Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Biopharmaceutical Industry Approaches to Facility Segregation for Viral Safety: An Effort from the Consortium on Adventitious Agent Contamination in Biomanufacturing.

Barone PW, Avgerinos S, Ballard R, Brussel A, Clark P, Dowd C, Gerentes L, Hart I, Keumurian FJ, Kindermann J, Leung JC, Ly N, Mink S, Minning S, Mullberg J, Murphy M, Nöske K, Parriott S, Shum B, Wiebe ME, Springs SL.

PDA J Pharm Sci Technol. 2019 Mar-Apr;73(2):191-203. doi: 10.5731/pdajpst.2018.008862. Epub 2018 Oct 25.

PMID:
30361281
2.

Quality of narrative operative reports in pancreatic surgery.

Wiebe ME, Sandhu L, Takata JL, Kennedy ED, Baxter NN, Gagliardi AR, Urbach DR, Wei AC.

Can J Surg. 2013 Oct;56(5):E121-7.

3.

Consistency and stability of recombinant fermentations.

Wiebe ME, Builder SE.

Dev Biol Stand. 1994;83:45-54. Review.

PMID:
7883099
4.

Process validation for cell culture-derived pharmaceutical proteins.

Lubiniecki AS, Wiebe ME, Builder SE.

Bioprocess Technol. 1990;10:515-41. Review.

PMID:
1367070
5.

Cell banking.

Wiebe ME, May LH.

Bioprocess Technol. 1990;10:147-60. Review.

PMID:
1367056
6.

Effect of immunosuppressants on OKT3 associated T cell activation: clinical implications.

Suthanthiran M, Wiebe ME, Stenzel KH.

Kidney Int. 1987 Sep;32(3):362-7.

7.

Inactivation of viruses in labile blood derivatives. II. Physical methods.

Horowitz B, Wiebe ME, Lippin A, Vandersande J, Stryker MH.

Transfusion. 1985 Nov-Dec;25(6):523-7.

PMID:
3934802
8.
9.

Markers of Venezuelan encephalitis virus which distinguish enzootic strains of subtype I-D from those of I-E.

Stanick DR, Wiebe ME, Scherer WF.

Am J Epidemiol. 1985 Aug;122(2):234-44. Review.

PMID:
3893103
10.

Activation of human macrophages. Comparison of other cytokines with interferon-gamma.

Nathan CF, Prendergast TJ, Wiebe ME, Stanley ER, Platzer E, Remold HG, Welte K, Rubin BY, Murray HW.

J Exp Med. 1984 Aug 1;160(2):600-5.

11.

Specificity of a monoclonal antibody for the NH2-terminal region of fibrin.

Kudryk B, Rohoza A, Ahadi M, Chin J, Wiebe ME.

Mol Immunol. 1984 Jan;21(1):89-94.

PMID:
6200769
12.

A monoclonal antibody with ability to distinguish between NH2-terminal fragments derived from fibrinogen and fibrin.

Kudryk B, Rohoza A, Ahadi M, Chin J, Wiebe ME.

Mol Immunol. 1983 Nov;20(11):1191-200.

PMID:
6656769
13.
14.
15.

Isolation and characterization of temperature-sensitive mutants of Venezuelan encephalitis virus.

Pancake BA, Harsanyi ZP, Wiebe ME, Emini EA, Scherer WF.

Virology. 1981 Apr 15;110(1):197-201. No abstract available.

PMID:
7210504
16.
17.
18.

Proposed antigenic classification of registered arboviruses I. Togaviridae, Alphavirus.

Calisher CH, Shope RE, Brandt W, Casals J, Karabatsos N, Murphy FA, Tesh RB, Wiebe ME.

Intervirology. 1980;14(5-6):229-32. No abstract available.

PMID:
6265396
19.

A hamster-attenuated, temperature-sensitive mutant of Venezuelan encephalitis virus.

Krieger JN, Scherer WF, Wiebe ME, Pancake BA, Harsanyi ZP.

Infect Immun. 1979 Sep;25(3):873-9.

20.

Heterogeneity of envelope polypeptides among strains of venezuelan encephalitis virus.

Wiebe ME, Scherer WF.

Virology. 1979 Apr 30;94(2):474-8. No abstract available.

PMID:
452424
21.

The mechanism of inhibition of reovirus replication by interferon.

Wiebe ME, Joklik TW.

Virology. 1975 Jul;66(1):229-40. No abstract available.

PMID:
1169850
22.

Isolation and characterization of two cell types of Coxiella burneti phase I.

Wiebe ME, Burton PR, Shankel DM.

J Bacteriol. 1972 Apr;110(1):368-77.

Supplemental Content

Loading ...
Support Center